Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12345678910111213...3637»
  • ||||||||||  Clinical, Review, Journal:  Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running? (Pubmed Central) -  May 30, 2023   
    Several randomized trials have proven that ALK inhibitors (ALK-Is) have greater efficacy with respect to platinum-based chemotherapy and that second/third generation ALK-Is are better than crizotinib in terms of improvements in median progression-free survival and brain metastases management...This review summarizes first-line randomized clinical trials of several ALK-Is and the management of brain metastases with a focus on ALK-I resistance mechanisms. The last section addresses future developments and challenges.
  • ||||||||||  MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions (Hilton Chicago, Grand Ballroom ) -  May 15, 2023 - Abstract #ASCO2023ASCO_7039;    
    This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc. Published data with alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements; clinical factors in the selection of which to administer Differential CNS permeability and intracranial response rates observed with approved ALK-targeted agents; implications for selection of treatment for patients with brain metastases Indications for and implications of repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for disease that is progressing on first-line ALK inhibition Principal efficacy and safety findings with entrectinib for NSCLC with a ROS1 rearrangement; integration into clinical practice Available data with, FDA breakthrough therapy designation for and ongoing evaluation of repotrectinib for NSCLC with a ROS1 rearrangement Key efficacy and safety results with selpercatinib or pralsetinib for patients with RET fusion-driven NSCLC, including those with previously untreated disease; optimal integration into therapy and selection between these agents Appropriate sequencing of immunotherapy for patients with metastatic NSCLC and targetable tumor mutations, including ALK, ROS1 and RET alterations
  • ||||||||||  Alecensa (alectinib) / Roche
    Enrollment closed, Trial completion date, Metastases:  A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  May 12, 2023   
    P3,  N=187, Active, not recruiting, 
    Published data with alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements; clinical factors in the selection of which to administer Differential CNS permeability and intracranial response rates observed with approved ALK-targeted agents; implications for selection of treatment for patients with brain metastases Indications for and implications of repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for disease that is progressing on first-line ALK inhibition Principal efficacy and safety findings with entrectinib for NSCLC with a ROS1 rearrangement; integration into clinical practice Available data with, FDA breakthrough therapy designation for and ongoing evaluation of repotrectinib for NSCLC with a ROS1 rearrangement Key efficacy and safety results with selpercatinib or pralsetinib for patients with RET fusion-driven NSCLC, including those with previously untreated disease; optimal integration into therapy and selection between these agents Appropriate sequencing of immunotherapy for patients with metastatic NSCLC and targetable tumor mutations, including ALK, ROS1 and RET alterations Unknown status --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2026
  • ||||||||||  Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
    Trial completion, Combination therapy, Metastases:  Alectinib in Combination With Bevacizumab in ALK Positive NSCLC (clinicaltrials.gov) -  Apr 27, 2023   
    P2,  N=40, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
    Anaplastic lymphoma kinase (ALK) and ROS 1 () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6456;    
    Majority of patients were never smokers. Opposite lung and bone were the most common site of metastases.
  • ||||||||||  Retrospective data, Journal:  CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. (Pubmed Central) -  Mar 31, 2023   
    These results indicated that alectinib could be associated with the best therapeutic efficacy and well-tolerance AEs in the treatment of ALK-positive NSCLC. In this initial case series, we describe CNS downstaging as a promising multidisciplinary treatment paradigm involving the upfront administration CNS-active systemic therapy and close MRI surveillance for extensive BrMs as a strategy to avoid upfront WBRT and to convert some patients into SRS candidates.
  • ||||||||||  Alecensa (alectinib) / Roche
    Trial completion, Trial completion date, Trial primary completion date:  Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns (clinicaltrials.gov) -  Mar 27, 2023   
    P=N/A,  N=1, Completed, 
    Based on these findings, the oral suspension of alectinib appears suitable for use in pediatric studies after appropriate dose adjustment relative to the capsule. Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Nov 2022 | Trial primary completion date: Jul 2023 --> Nov 2022
  • ||||||||||  Alecensa (alectinib) / Roche
    Saved by the Birds: Suspicion for Hypersensitivity Pneumonitis Leading to the Diagnosis of Pulmonary Lymphangitic Carcinomatosis (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_8771;    
    She was seen several times by her primary care physician who prescribed azithromycin, a combination fluticasone propionate and salmeterol inhaler, and a short course of prednisone...She was started on alectinib, an anaplastic lymphoma kinase inhibitor targeted chemotherapy, with almost complete resolution of her symptoms.In this case, we describe a patient with an appropriate symptomatic and exposure history, along with radiologic findings highly suggestive of hypersensitivity pneumonitis (HP)...HP is a challenging diagnosis to confirm and this case highlights the critical role of a comprehensive differential diagnostic workup inclusive of bronchoscopy with lung biopsy when considering this diagnosis. In addition, while PLC is a rare diagnosis, this case also demonstrates the importance of considering it as a differential diagnosis when certain forms of interstitial lung disease are suspected.
  • ||||||||||  Alecensa (alectinib) / Roche
    A Case of EML4-ALK Fusion Lung Adenocarcinoma in an 18-year-old Patient (Walter E. Washington Convention Center, Area H, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_8232;    
    Treatment with tyrosine kinase inhibitors such as alectinib have improved outcomes in patients with this oncogenic fusion who typically have advanced disease at the time of diagnosis...This case calls attention to oncogenic driver mutations that can cause non-small cell lung cancer in previously healthy young non-smokers. Pediatric providers should consider this entity as well as endobronchial ultrasound with transbronchial needle aspiration for timely diagnosis and initiation of targeted therapies.